Toripalimab  (Synonyms: JS-001)

Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

PDCD1/PD-1/CD279

Toripalimab specifically binds to PD-1 (EC₅₀ 21 nmol/L) and inhibits binding of PD-1 to PD-L1 [IC₅₀ 3.0 nmol/L (≈ 0.5 μg/mL)] and PD-L2 (IC₅₀ 3.1 nmol/L) in 293F cells transfected with PD-1 plasmids^[2].
Toripalimab (0.01–10 μg/mL) dose-dependently promotes human T-cell proliferation^[2].
Toripalimab promotes interferon-γ and TNF-α secretion in activated human peripheral blood mononuclear cell (PBMC)-derived T cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Toripalimab (0.3-10 mg/kg; i.p.; twice a week, total 6 times) exhibits substantial tumor suppressive efficacy in a dose-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5133  [NCBI]

Q15116

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

147.3 kDa

1924598-82-2

Liquid

Colorless to light yellow

[Toripalimab]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized PD-1 Protein, Human (143a.a, HEK293, His, HY-7396) can bind Toripalimab. The EC₅₀ for this effect is 7.504 ng/mL.
• 
  Flow cytometric analysis of 1X10⁶ 10 ng/mL PMA and 1 μg/mL Ionomycin co-stimulated Jurkat cells(24h) labeling Toripalimab (HY-P9978, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Lin Zhang, et al. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.  [Content Brief]

  [2]. Keam SJ. Toripalimab: First Global Approval. Drugs. 2019 Apr;79(5):573-578.  [Content Brief]

  [3]. Liu H, et al. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. MAbs. 2019 May/Jun;11(4):681-690.  [Content Brief]